Clinical features of schizophrenia with enhanced carbonyl stress

Schizophrenia Bulletin

Volumn 40, Issue 5, 2014, Pages 1040-1046

  Miyashita, Mitsuhiro ^a,b,c   Arai, Makoto ^a   Kobori, Akiko ^a   Ichikawa, Tomoe ^a   Toriumi, Kazuya ^a   Niizato, Kazuhiro ^b   Oshima, Kenichi ^b   Okazaki, Yuji ^b   Yoshikawa, Takeo ^d   Amano, Naoji ^c   Miyata, Toshio ^e   Itokawa, Masanari ^a,b,d  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbonyl stress; Clinical features; Pentosidine; Treatment resistant schizophrenia; Vitamin B6

Indexed keywords

CARBONYL DERIVATIVE; NEUROLEPTIC AGENT; PENTOSIDINE; PYRIDOXAL; PYRIDOXINE; ARGININE; BIOLOGICAL MARKER; LYSINE;

ADULT; ARTICLE; CLINICAL FEATURE; EDUCATIONAL STATUS; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN CARBONYLATION; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIPSYCHOTIC AGENTS; ARGININE; BIOMARKERS; FEMALE; HOSPITALIZATION; HUMANS; LYSINE; MALE; MIDDLE AGED; PROTEIN CARBONYLATION; SCHIZOPHRENIA; VITAMIN B 6;

EID: 84906933729     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbt129     Document Type: Article

References (29)

1. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int. 1999;55: 389-399.
2. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care. 2011;34: 442-447.
3. Koyama Y, Takeishi Y, Arimoto T, et al. High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. J Card Fail. 2007;13: 199-206.
4. Meli M, Perier C, Ferron C, et al. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis. 2002;4: 93-96.
5. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 1998;4: 1025-1031.
6. Arai M, Yuzawa H, Nohara I, et al. Enhanced carbonyl stress in a subpopulation of schizophrenia. Arch Gen Psychiatry. 2010;67: 589-597.
7. Miyata T, Taneda S, Kawai R, et al. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin- containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA. 1996;93: 2353-2358.
8. Bisp MR, Bor MV, Heinsvig EM, Kall MA, Nexø E. Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal Biochem. 2002;305: 82-89.
9. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45: 789-796.
10. Azorin JM, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 2001;158: 1305-1313.
11. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155: 751-760.
12. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001;58: 965-972.
13. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63: 524-529.
14. McEvoy JP, Lieberman JA, Stroup TS, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163: 600-610.
15. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329: 162-167.
16. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull. 1991;17: 247-261.
17. Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Can Psychiatr Assoc J. 1973;18: 377-383.
18. Bucci L. Pyridoxine and schizophrenia. Br J Psychiatry. 1973;122: 240.
19. Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol. 1999;22: 241-243.
20. Lerner V, Liberman M. Movement disorders and psychotic symptoms treated with pyridoxine: a case report. J Clin Psychiatry. 1998;59: 623-624.
21. Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60: 265-269.
22. Sandyk R, Pardeshi R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci. 1990;52: 225-232.
23. Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients: preliminary report. Commun Psychopharmacol. 1977;1: 119-122.
24. Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2002;63: 54-58.
25. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373: 31-41.
26. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353: 1209-1223.
27. Arai M, Koike S, Oshima N, et al. Idiopathic carbonyl stress in a drug-naive case of at-risk mental state. Psychiatry Clin Neurosci. 2011;65: 606-607.
28. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002;159: 1080-1092.
29. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64: 31-39.